Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SP Funds S&P 500 Sharia Industry Exclusions ETF vs GeneDx Holdings Corp — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $58.52, while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| SPUS | WGS | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $59.51 | $167.51 |
52-Week Low | $46.65 | $34.51 |
Market Cap | — | $2.56B |
Enterprise Value | — | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPUS trades at $58.72, down 0.53% on the day, with technical indicators showing a neutral to slightly bullish bias. The stock exhibits a narrow trading range with key support and resistance clustered around $58-$59. Recent corporate actions include small quarterly dividends, but key fundamental valuation and profitability ratios are not publicly reported, limiting traditional analysis. No major recent news or earnings data is available to drive sentiment.
The outlook for SPUS is clouded by a lack of accessible fundamental data, presenting a challenge for valuation. The primary opportunity lies in potential undiscovered value, while the significant risk is the inability to assess the company's financial health, earnings power, or competitive position, making it a speculative holding dependent on broader market trends.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
